Podcasts about stood

Learn more about your ad choices. Visit megaphone.fm/adchoices

Michael Bumpus and Bryan Walters, filling in for Brock and Salk, dive into a few things that jumped out to them during the weekend for the Mariners. They then bring on Mariners Insider Shannon Drayer to get her insight on the road trip, Cal raleigh and more. In Blue 88, topics include Noah Fant, the Seahawks linebacker group and DK Metcalf.

Paul: A Man of Grace and Grit

Acts 25:13-26:32 / June 25-27, 2025 Pastor Chuck Swindoll presents Paul's final trial before Festus and King Agrippa in Acts 26. He stood tall by boldly proclaiming the truth of the Gospel. From the Series: Paul: A Man of Grace and Grit read more

JACKIE HILL PERRY, TIPHANI MONTGOMERY, MARCUS ROGERS PLEASE ALWAYS READ THIS INFO BOX WHEN YOU VISIT TMVP BLOG. ***Especially please do not send any gift to this ministry unless you have read & understood the instructions below.*** DO NOT INTERACT WITH ANYONE ASKING FOR DONATIONS. Thank you. WEBSITE: WWW.THE-MASTERS-VOICE.COM PLEASE READ CAREFULLY: If you'd like to support this work, it is appreciated. Kindly use PayPal or email me for other options at mastersvoice@mail.com, and *please* give me some time to respond. If using PayPal PLEASE DO NOT send any gift with "Purchase Protection". I have an ordinary PayPal account, not a seller marketplace, so please do not damage my account by using "purchase protection" on your donation (as if I were making a sale to you). If you are not sure (especially if you sent in the past), please check the format of your gift on the PayPal receipt before sending. It is a freewill offering, I am not selling goods or services. Please use *only* the "Friends & Family" sending option. If you're outside the USA please DO NOT use PayPal, contact me instead at the email listed here & allow me a good window to respond. Thank you, God bless. PayPal ------- mastersvoice@mail.com.

Freak Accident? Hollywood Lives.

Learn more about your ad choices. Visit megaphone.fm/adchoices

Earthly heroes are those who stand tall in moments when others shrink back. They use their voice to speak truth, and their actions follow suit. In those moments of standing tall, they seem invincible.Pastor Chuck Swindoll presents Paul's final trial before Festus and King Agrippa in Acts 26. He stood tall by boldly proclaiming the truth of the gospel.Those who stand tall might not know the impact of their words or actions, but they do what is right regardless. They leave the results to God. How will you stand tall in response to this message? To support this ministry financially, visit: https://www.oneplace.com/donate/82/29

Paul: A Man of Grace and Grit

Femi Abebefe & Jared Smith recap last night's NBA Draft, and share their thoughts on the top half of the draft To learn more about listener data and our privacy practices visit: https://www.audacyinc.com/privacy-policy Learn more about your ad choices. Visit https://podcastchoices.com/adchoices

Acts 25:13-26:32 / June 25-27, 2025 Pastor Chuck Swindoll presents Paul's final trial before Festus and King Agrippa in Acts 26. He stood tall by boldly proclaiming the truth of the Gospel. From the Series: Paul: A Man of Grace and Grit read more

Today, I interview Junie Moon, who grew up bright and bubbly, until one look from her mother made her feel unloved. Her free spirit met a controlling household where even a glance could silence her. By eight, she had learned to dim her light just to stay safe. Being cheerful and expressive got her labeled, and rejected.Bullied through middle school, silent in high school, Junie carried this fear of being seen well into adulthood. It shaped her relationships, her body, and her belief that her voice didn't matter.But something changed. A moment came when she couldn't stay quiet any longer—not for herself, and not for the person she loved most. That moment set her on the path to healing.Today, Junie helps women uncover the hidden fears that silence them and teaches them how to build trust in themselves again, so they can speak up, show up, and call in lasting love.__________________Junie Moon is the CEO of Midlife Love Out Loud, a Global Love Mentor, bestselling author, women's empowerment leader, and Certified Shadow Work® Coach. For over 30 years, she has helped thousands of women claim their birthright: the freedom to love themselves without apology, and attract lifelong, soul-aligned love because of it.Her work is grounded in transformation from the inside out. Junie guides women in midlife on a powerful journey of self-discovery, where the focus isn't just on finding a partner—it's about building deep self-trust, confidence, and inner alignment. When women feel whole and safe in their own skin, the love they've been longing for begins to arrive with ease.She's been featured on News 12 New Jersey, Blog Talk Radio, Thrive Global, and Authority Magazine. Her short film Shed the Shame, which she produced and starred in, was featured at Newark International. Junie is the international bestselling author of Loving the Whole Package: Shed the Shame and Live Life Out Loud, an award-winning speaker, and the host of the Midlife Love Out Loud podcast. She's shared the stage with John Gray, Marci Shimoff, Sheri Winston, and other leading voices in the field of personal growth.__________________Find Junie here:Junie's Website: https://midlifeloveoutloud.com/ Facebook: https://www.facebook.com/midlifeloveoutloud FB Group: https://www.facebook.com/groups/1962269713813419 Instagram: https://www.instagram.com/midlifeloveoutloud Linkedin: https://www.linkedin.com/in/love-coach-junie-moon-995262a/ Youtube: https://www.youtube.com/@MidlifeLoveOutLoud Podcast: https://podcasts.apple.com/us/podcast/midlife-love-out-loud-podcast/id1477913318 Free gift: http://midlifeloveoutloud.com/innercriticgift Support the showI'm Dr. Doreen Downing and I help people find their voice so they can speak without fear. Get the Free 7-Step Guide to Fearless Speaking https://www.doreen7steps.com​.

Send us a textBuckle up for this one, its a really amazing, and extraordinary story of courage, will power, and total inspiration. Lindsay Boudreau had a very rare underlying illness, CMT Disease, that meant she had weakened sensations in her feet, and so she couldn't feel the pain of an infection caused by a nail she had stepped on, one day while walking. Over many weeks, she became very ill, and very weak, and doctors simply couldn't find what was wrong with her until it was too late. Eventually, on realizing the spreading infection could kill her, they took steps to amputate. Lindsay is a beacon of hope for those who are living life after limb loss, and even has a coaching business, helping other limb loss survivors and other medical trauma survivors, by building hope and resilience and practicing mindfulness and wellbeing. Simply amazing!Links for Lindsay:Insta: https://www.instagram.com/lindsayboudreaucoaching/Website: https://www.lindsayboudreau.com/FB: https://www.facebook.com/groups/youramplifiedlifeprogramThe Ryan Pyle PodcastThe Ryan Pyle Podcast with Ryan Pyle is a podcast and radio show hosted by adventure...Listen on: Apple Podcasts SpotifySupport the show

Jamie opens up about ADHD, financial struggles, addiction, a near-fatal car accident, and ultimately, recovery through faith. Brayden and Joel sits down with Jamie to explore how such challenges shaped his life and how God's grace led to transformation.⏱ Timestamps:00:00 – Medication, focus, and learning strategies01:42 – Talking accents and travel dreams (Canada)04:40 – Ministry beginnings at Blakehurst Church08:07 – Post-high school path: IT traineeship and work life11:31 – Early fascination with technology13:47 – AV, music, and IT: Church influence and passions16:18 – Turning 18: Financial impulsivity and growing debt18:16 – ADHD medication, anxiety, and distance from God20:44 – Debt cycles and emotional toll23:32 – Addiction struggles: Alcohol, gambling, and depression25:10 – Church neglect and hitting rock bottom30:27 – Chloe's support and renewed faith37:33 – Stood down from ministry: heartbreak and confusion39:09 – Leaving the church, Chloe's decision to follow40:43 – Starting again at Soul Revival Church (Cronulla)50:10 – The car accident: Emergency response saves a life51:14 – Facial injuries and coma: LaFort III fracture55:37 – 8.5-hour surgery and sinuses removed01:01:03 – ICU confusion and becoming aware01:02:50 – Post-traumatic amnesia and brain injury01:03:14 – OT cognitive tests and memory recall01:07:34 – Awake arm surgery with nerve block01:14:14 – Miracle recovery with minimal long-term damage01:16:49 – Regaining self, healing, and reflection01:20:40 – Life-changing moment: quitting alcohol and trusting God01:26:23 – Advice to younger self: Let God take control01:28:00 – Trusting God through pain01:29:52 – A miraculous testimony of survival01:31:01 – Mental health, joy, and serving others#Testimony #FaithAndRecovery #MentalHealth #ChristianStory #Transformation

Earthly heroes are those who stand tall in moments when others shrink back. They use their voice to speak truth, and their actions follow suit. In those moments of standing tall, they seem invincible.Pastor Chuck Swindoll presents Paul's final trial before Festus and King Agrippa in Acts 26. He stood tall by boldly proclaiming the truth of the gospel.Those who stand tall might not know the impact of their words or actions, but they do what is right regardless. They leave the results to God. How will you stand tall in response to this message? To support this ministry financially, visit: https://www.oneplace.com/donate/82/29

Paul: A Man of Grace and Grit

Acts 25:13-26:32 / June 25-27, 2025 Pastor Chuck Swindoll presents Paul's final trial before Festus and King Agrippa in Acts 26. He stood tall by boldly proclaiming the truth of the Gospel. From the Series: Paul: A Man of Grace and Grit read more

Acts 25:13-26:32 / June 25-27, 2025 Pastor Chuck Swindoll presents Paul's final trial before Festus and King Agrippa in Acts 26. He stood tall by boldly proclaiming the truth of the Gospel. From the Series: Paul: A Man of Grace and Grit read more

Dr. Vamsi Velcheti and Dr. Nate Pennell discuss novel treatment approaches in small cell and non-small cell lung cancer that were featured at the 2025 ASCO Annual Meeting. TRANSCRIPT Dr. Vamsi Velcheti: Hello, I'm Dr. Vamsi Velcheti, your guest host of the ASCO Daily News Podcast. I'm a professor of medicine and chief of hematology and oncology at the Mayo Clinic in Jacksonville, Florida. The 2025 ASCO Annual Meeting featured some exciting advancements in small cell lung cancer, targeted therapies for non-small cell lung cancer, and other novel [treatment] approaches. Today, I'm delighted to be joined by Dr. Nate Pennell to discuss some of the key abstracts that are advancing the lung cancer field. Dr. Pennell is the co-director of the Cleveland Clinic Lung Cancer Program and also the vice chair of clinical research at the Taussig Cancer Institute. Our full disclosures are available in the transcript of this episode. Nate, it's great to have you back on the podcast. Thanks so much for being here. Dr. Nate Pennell: Thanks, Vamsi. Always a pleasure. Dr. Vamsi Velcheti: Let's get started, and I think the first abstract that really caught my attention was Abstract 8516, “The Randomized Trial of Relevance of Time of Day of Immunotherapy for Progression-Free and Overall Survival in Patients With Non-Small Cell Lung Cancer.” What are your thoughts about this, Nate? Dr. Nate Pennell: I agree. I thought this was one of the most discussed abstracts, certainly in the lung cancer session, but I think even outside of lung cancer, it got some discussion. So, just to put this in perspective, there have been a number of publications that have all been remarkably consistent, and not just in lung cancer but across multiple cancer types, that immunotherapy, immune checkpoint inhibitors, are commonly used. And all of them have suggested, when looking at retrospective cohorts, that patients who receive immune checkpoint inhibitors earlier in the day – so in the morning or before the early afternoon – for whatever reason, appear to have better outcomes than those who get it later in the day, and this has been repeated. And I think many people just sort of assumed that this was some sort of strange association and that there was something fundamentally different from a prognostic standpoint in people who came in in the morning to get their treatment versus those who came later in the afternoon, and that was probably the explanation. The authors of this randomized trial actually decided to test this concept. And so, about 210 patients with previously untreated advanced non-small cell lung cancer were randomly assigned to get chemo and immune checkpoint inhibitor – either pembrolizumab or sintilimab – and half of them were randomly assigned to get the treatment before 3 PM in the afternoon, and half of them were assigned to get it after 3 PM in the afternoon. And it almost completely recapitulated what was seen in the retrospective cohorts. So, the median progression-free survival in those who got earlier treatment was 13.2 months versus only 6.5 months in those who got it later in the day. So, really enormous difference with a hazard ratio of 0.43, which was statistically significant. And perhaps even more striking, the median overall survival was not reached in the early group versus 17.8 months in the late group with a hazard ratio of 0.43, also highly statistically significant. Even the response rate was 20% higher in the early patients; 75% response rate compared to 56% in the late-time-of-day patients. So very consistent across all measures of efficacy with pretty good matched characteristics across the different groups. And so, I have to tell you, I don't know what to make of this. I certainly was a skeptic about the retrospective series, but now we have a prospective randomized trial that shows essentially the same thing. So, maybe there is a difference between getting treated in the morning, although I have yet to hear someone give a very good mechanistic explanation as to why this would be. What were your thoughts on this? Dr. Vamsi Velcheti: It's indeed fascinating, Nate, and I actually think this was a very interesting abstract. Really, I was caught off guard looking at the data. I mean, if it were a drug, we would be so excited, right? I mean, with those kind of survival benefits. I don't know. I think circadian rhythm probably has something to do with it, like different cytokine profiles at the time of administration. I mean, who knows? But I think it's a randomized trial, and I think I would expect to see a mad rush for treatment appointments early in the morning given this, and at least I want my patients to come in first thing in the morning. It'll be interesting to see. Dr. Nate Pennell: It's important to point out that in this study, everyone got chemo and immunotherapy. And, at least in our cancer center, most patients who are getting platinum-doublet chemotherapy and immunotherapy actually do get treated earlier in the day already, just because of the length of the infusion appointment that's needed. So it really is oftentimes people getting single-agent immunotherapy who are often getting the later, shorter visits. But if you have a choice, I think it would be very reasonable to have people treated earlier in the day. And I do think most of the impressions that I got from people about this is that they would like to see it reproduced but certainly well worth further investigation. And I personally would like to see more investigation into what the rationale would be for this because I still can't quite figure out, yes, if you got it at, say, you know, 5 PM, that's later in the day and I can understand that maybe your immune system is somewhat less receptive at that point than it would be in the morning. But because these checkpoint inhibitors have such long half-lives, it's still in your system the next morning when your immune system is supposedly more receptive. So I don't quite understand why that would be the case. Well, let's move on to the next study. I would like to hear your thoughts on Abstract 8515, “Plasma-Guided, Adaptive First-Line Chemoimmunotherapy for Non-Small Cell Lung Cancer.” Dr. Vamsi Velcheti: Yeah, this was another abstract that seems to be really interesting in my opinion. I think there's kind of a lot of emphasis lately on ctDNA and MRD-based assays to monitor disease. In the lung cancer space, we haven't had a lot of clinical trials looking at this prospectively, and this was one of those pilot studies where they looked at circulating free DNA (cfDNA)-based response-adaptive strategy for frontline patients who are PD-L1 positive. So, patients started with pembrolizumab monotherapy, and based on plasma molecular response after 2 cycles, those patients without response received early treatment intensification with a platinum doublet. So the approach essentially was to reduce the chemotherapy exposure in patients who respond to immunotherapy. And only about 17.5% of the patients on the trial received chemotherapy based on lack of molecular response. So, in this trial, what they found was patients with the cfDNA response had a markedly improved PFS of 16.4 months versus 4.8 months. So essentially, like, this is a really nice study to set a foundation on which we have to do larger studies to incorporate molecular markers trying to look at cfDNA response to inform treatment strategy, either escalation or de-escalation strategies. So, I thought it was a very interesting study. Dr. Nate Pennell: Yeah. I mean, we always have this question for patients, “Should they get immunotherapy alone or combined with chemo?” and I think this certainly is intriguing, suggesting that there may be ways you can monitor people and perhaps rescue those that aren't going to respond to single agent. I'd like to see a randomized trial against, you know, this strategy, perhaps against everyone getting, say, chemoimmunotherapy or make sure that you're not potentially harming people by doing this strategy. But I agree, it's time to move beyond just observing that cell-free DNA is prognostic and important and start using it to actually guide treatment. Dr. Vamsi Velcheti: Yeah, and I would just caution though, like, you know, I think we need more data, but, however, it's certainly a very interesting piece of data to kind of help inform future trials. So, there was another abstract that caught my attention, and I think this would be a very interesting abstract in the EGFR space. Abstract 8506, "Patritumab Deruxtecan (HER3-DXd) in Resistant EGFR-Mutant Advanced Non-Small Cell Lung Cancer Patients After Third-Generation EGFR TKI," it's the HERTHENA-Lung02 study. What do you think about the results of this study? Dr. Nate Pennell: Yeah, this was, I would say, very widely anticipated and ultimately a little disappointing, despite being a positive trial. So, these are patients with EGFR-mutant non-small cell lung cancer who have progressed after a third-generation EGFR TKI like osimertinib. This is really an area of major unmet need. We do have drugs like amivantamab in this space, but still definitely an area where essentially patients move from having a highly effective oral therapy to being in the realm of chemotherapy as their best option. So, this HER3 antibody-drug conjugate, patritumab deruxtecan, had some good single-arm data for this. And we're sort of hoping this would become an available option for patients. This trial was designed against platinum-doublet chemotherapy in this setting and with a primary endpoint of progression-free survival. And it actually was positive for improved progression-free survival compared to chemo with a hazard ratio of 0.77. But when you look at the medians, you can see that the median PFS was only 5.8 versus 5.4 months. It was really a modest difference between the two arms. And on the interim analysis, it appeared that there will not be a difference in overall survival between the two arms. In fact, the hazard ratio at the interim analysis was 0.98 for the two arms. So based on this, unfortunately, the company that developed the HER3-DXd has withdrawn their application to the FDA for approval of the drug, anticipating that they probably wouldn't get past approval without that overall survival endpoint. So, unfortunately, probably not, at least for the near future, going to be a new option for these patients. Dr. Vamsi Velcheti: Yeah, I think this is a space that's clearly an unmet need, and this was a big disappointment, I should say. I think all of us were going into the meeting anticipating some change in the standard of care here. Dr. Nate Pennell: Yeah, I agree. It was something that I was telling patients, honestly, that I was expecting this to be coming, and so now, definitely a bit of a disappointment. But it happens and, hopefully, it will still find perhaps a role or other drugs with a similar target. Certainly an active area. Well, let's leave the EGFR-mutant space and move into small cell. There were a couple of very impactful studies. And one of them was Abstract 8006, “Lurbinectedin Plus Atezolizumab as First-Line Maintenance Treatment in Patients With Extensive-Stage Small Cell Lung Cancer, Primary Results from the Phase III IMforte Trial.” So, what was your impression of this? Dr. Vamsi Velcheti: Yeah, I think this is definitely an interesting study, and small cell, I remember those days when we had barely any studies of small cell at ASCO, and now we have a lot of exciting developments in the small cell space. It's really good to see. The IMforte trial is essentially like a maintenance lurbinectedin trial with atezolizumab maintenance. And the study was a positive trial. The primary endpoint was a PFS, and the study showed improvement in both PFS and OS with the addition of lurbinectedin to atezolizumab maintenance. And definitely, it's a positive trial, met its primary endpoint, but I always am a little skeptical of adding maintenance cytotoxic therapies here in this setting. In my practice, and I'd like to hear your opinion, Nate, most patients with small cell after 4 cycles of a platinum doublet, they're kind of really beaten up. Adding more cytotoxic therapy in the maintenance space is going to be tough, I think, for a lot of patients. But also, most importantly, I think this rapidly evolving landscape for patients with small cell lung cancer with multiple new, exciting agents, actually like some FDA-approved like tarlatamab, also like a lot of these emerging therapeutics like I-DXd and other ADCs in this space. You kind of wonder, is it really optimal strategy to bring on like another cytotoxic agent right after induction chemotherapy, or do you kind of delay that? Or maybe have like a different strategy in terms of maintenance. I know that the tarlatamab maintenance trial is probably going to read out at some point too. I think it's a little challenging. The hazard ratio is also 0.73. As I said, it's a positive trial, but it's just incremental benefit of adding lurbi. And also on the trial, we need to also pay attention to the post-progression second-line treatments, number of patients who received tarlatamab or any other investigational agents.  So I think it's a lot of questions still. I'm not quite sure I'd be able to embrace this completely. I think a vast majority of my patients might not be eligible anyway for cytotoxic chemotherapy maintenance right away, but yeah, it's tough. Dr. Nate Pennell: Yeah. I would call this a single and not a home run. It definitely is real. It was a real overall survival benefit. Certainly not surprising that a maintenance therapy would improve progression-free survival. We've known that for a long time in small cell, but first to really show an overall survival benefit. But I completely agree with you. I mean, many people are not going to want to continue further cytotoxics after 4 cycles of platinum-doublet chemo. So I would say, for those that are young and healthy and fly through chemo without a lot of toxicity, I think certainly something worth mentioning. The problem with small cell, of course, is that so many people get sick so quickly while on that observation period after first-line chemo that they don't make it to second-line treatment. And so, giving everyone maintenance therapy essentially ensures everyone gets that second-line treatment. But they also lose that potentially precious few months where they feel good and normal and are able to be off of treatment. So, I would say this is something where we're really going to have to kind of sit and have that shared decision-making visit with patients and decide what's meaningful to them. Dr. Vamsi Velcheti: Yeah, I agree. The next abstract that was a Late-Breaking Abstract, 8000, “Overall Survival of Neoadjuvant Nivolumab Plus Chemotherapy in Patients With Resectable Non-Small Cell Lung Cancer in CheckMate-816.” This was a highly anticipated read-out of the OS data from 816. What did you make of this abstract? Dr. Nate Pennell: Yeah, I thought this was great. Of course, CheckMate-816 changed practice a number of years ago when it first reported out. So, this was the first of the neoadjuvant or perioperative chemoimmunotherapy studies in resectable non-small cell lung cancer. So, just to review, this was a phase 3 study for patients with what we would now consider stage II or stage IIIA resectable non-small cell lung cancer. And they received three cycles of either chemotherapy or chemotherapy plus nivolumab, and that was it. That was the whole treatment. No adjuvant treatment was given afterwards. They went to resection. And patients who received the chemoimmunotherapy had a much higher pathologic complete response rate and a much better event-free survival. And based on this, this regimen was approved and, I think, at least in the United States, widely adopted.  Now, since the first presentation of CheckMate 816, there have been a number of perioperative studies that have included an adjuvant component of immunotherapy – KEYNOTE-671, the AEGEAN study – and these also have shown improved outcomes. The KEYNOTE study with pembrolizumab also with an overall survival benefit. And I think people forgot a little bit about CheckMate-816. So, this was the 5-year overall survival final analysis. And it did show a statistically and, I think, clinically meaningful difference in overall survival with the 3 cycles of neoadjuvant chemo-nivo compared to chemo with a hazard ratio of 0.72. The 5-year overall survival of 65% in the chemo-IO group versus 55% with the chemo alone. So a meaningful improvement. And interestingly, that hazard ratio of 0.72 is very similar to what was seen in the peri-operative pembro study that included the adjuvant component. So, very much still relevant for people who think that perhaps the value of those neoadjuvant treatments might be really where most of the impact comes from this type of approach. They also gave us an update on those with pathologic complete response, showing really astronomically good outcomes. If you have a pathologic complete response, which was more than a quarter of patients, the long-term survival was just phenomenal. I mean, 95% alive at 5 years if they were in that group and suggesting that in those patients at least, the adjuvant treatment may not be all that important.  So, I think this was an exciting update and still leaves very much the open question about the importance of continuing immunotherapy after surgery after the neoadjuvant component. Dr. Vamsi Velcheti: Yeah, I completely agree, Nate. I think the million-dollar question is: “Is there like a population of patients who don't have complete response but like maybe close to complete response?” So, would you like still consider stopping adjuvant IO? I probably would not be comfortable, but I think sometimes, you know, we all have patients who are like very apprehensive of continuing treatments. So, I think that we really need more studies, especially for those patients who don't achieve a complete CR. I think trying to find strategies for like de-escalation based on MRD or other risk factors. But we need more trials in that space to inform not just de-escalation, but there are some patients who don't respond at all to a neoadjuvant IO. So, there may be an opportunity for escalating adjuvant therapies. So, it is an interesting space to watch out for. Dr. Nate Pennell: No, absolutely. Moving to KRAS-mutant space, so our very common situation in patients with non-small cell lung cancer, we had the results of Abstract 8500, “First-Line Adagrasib With Pembrolizumab in Patients With Advanced or Metastatic KRASG12C-Mutated Non-Small Cell Lung Cancer” from the phase 2 portion of the KRYSTAL-7 study. Why was this an interesting and important study? Dr. Vamsi Velcheti: First of all, there were attempts to kind of combine KRASG12C inhibitors in the past with immune checkpoint inhibitors, notably sotorasib with pembrolizumab. Unfortunately, those trials have led to like a lot of toxicity, with increased especially liver toxicity, which was a major issue. This is a phase 2 study of adagrasib in combination with pembrolizumab, and this is a study in the frontline setting in patients with the G12C-mutant metastatic non-small cell lung cancer. And across all the PD-L1 groups, the ORR was 44%, and the median PFS was 11 months, comparable to the previous data that we have seen with adagrasib in this setting. So it's not like a major improvement in clinical efficacy. However, I think the toxicity profile that we were seeing was slightly better than the previous trials in combination with sotorasib, but you still have a fair amount of transaminitis even in the study. At this point, this is not ready for clinical primetime. I don't think we should be using sotorasib or adagrasib in the frontline or even in the second line in combination with checkpoint inhibitors. Combining these drugs with checkpoint inhibitors in the clinical practice might lead to adverse outcomes. So, we need to wait for more data like newer-generation G12C inhibitors which are also being studied in combination, so we'll have to kind of wait for more data to emerge in this space. Dr. Nate Pennell: I agree, this is not immediately practice changing. This is really an attempt to try to combine targeted treatment with immune checkpoint inhibitor. And I agree with you that, you know, it does appear to be perhaps a little bit better tolerated than some of the prior combinations that have tried in this space. The outcomes overall were not that impressive, although in the PD-L1 greater than 50%, it did have a better response rate perhaps than you would expect with either drug alone. And I do think that the company is focusing on that population for a future randomized trial, which certainly would inform this question better. But in the meantime, I agree with you, there's a lot of newer drugs that are coming along that potentially may be more active and better tolerated. And so, I'd say for now, interesting but we'll wait and see. Dr. Vamsi Velcheti: Yeah, so now moving back again to small cell. So, there was a Late-Breaking Abstract, 8008. This is a study of tarlatamab versus chemotherapy as second-line treatment for small cell lung cancer. They presented the primary analysis of the phase III DeLLphi-304 study. What do you think about this? Dr. Nate Pennell: Yeah, I thought this was really exciting. This was, I would say, perhaps the most important lung study that was presented. Tarlatamab is, of course, the anti-DLL3 bispecific T-cell engager compound, which is already FDA approved based on a prior single-arm phase II study, which showed a very nice response rate as a single agent in previously treated small cell lung cancer and relatively manageable side effects, although somewhat unique to solid tumor docs in the use of these bispecific drugs in things like cytokine release syndrome and ICANS, the neurologic toxicities. So, this trial was important because tarlatamab was approved, but there were also other chemotherapy drugs approved in the previously treated space. And so, this was a head-to-head second-line competition comparison between tarlatamab and either topotecan, lurbinectedin, or amrubicin in previously treated small cell patients with a primary endpoint of overall survival. So, a very well-designed trial. And it did show, I think, a very impressive improvement in overall survival with a median overall survival in the tarlatamab group of 13.6 months compared to 8.3 months with chemotherapy, hazard ratio of 0.6. And progression-free survival was also longer at 4.2 months versus 3.2 months, hazard ratio of 0.72. In addition to showing improvements in cancer-related symptoms that were improved in tarlatamab compared to chemotherapy, there was actually also significantly lower rates of serious treatment-related adverse events with tarlatamab compared to chemotherapy. So, you do still see the cytokine release syndrome, which is seen in most people but is manageable because these patients are admitted to the hospital for the first two cycles, as well as a significant number of patients with neurologic side effects, the so-called ICANS, which also can be treated with steroids. And so, I think based upon the very significant improvement in outcomes, I would expect that this should become our kind of standard second-line treatment since it seems to be much better than chemo. However, tarlatamab is definitely a new drug that a lot of places are not used to using, and I think a lot of cancer centers, especially ones that aren't tied to a hospital, may have questions about how to deal with the CRS. So, I'm curious your thoughts on that. Dr. Vamsi Velcheti: Yeah, thank you, Nate. And I completely agree. I think the data looked really promising, and I've already been using tarlatamab in the second-line space. The durability of response and overall, having used tarlatamab quite a bit - like, I participated in some of the early trials and also used it as standard of care - tarlatamab has unique challenges in terms of like need for hospitalization for monitoring for the first few treatments and make sure, you know, we monitor those patients for CRS and ICANS. But once you get past that initial administration and monitoring of CRS, these patients have a much better quality of life, they're off chemotherapy, and I think it's really about the logistics of actually administering tarlatamab and coordination with the hospital and administration in the outpatient setting. It's definitely challenging, but I think it definitely can be done and should be done given what we are seeing in terms of clinical efficacy here. Dr. Nate Pennell: I agree. I think hospital systems now are just going to have to find a way to be able to get this on formulary and use it because it clearly seems to be more effective and generally better tolerated by patients. So, should move forward, I think. Finally, there's an abstract I wanted to ask you about, Abstract 8001, which is the “Neoadjuvant osimertinib with or without chemotherapy versus chemotherapy alone in resectable epidermal growth factor receptor-mutated non-small cell lung cancer: The NeoADAURA Study”. And this is one that I think was also fairly highly anticipated. So, what are your thoughts? Dr. Vamsi Velcheti: You know, I wasn't probably surprised with the results, and I believe we were all expecting a positive trial, and we certainly were handed a positive trial here. It's a phase III trial of osimertinib and chemotherapy or osimertinib in the neoadjuvant space followed by surgery, followed by osimertinib. It's a global phase 3 trial and very well conducted, and patients with stage II to stage IIIB were enrolled in the study. And in the trial, patients who had a neoadjuvant osimertinib with or without chemotherapy showed a significant improvement in major pathologic response rates over chemotherapy alone. And the EFS was also positive for osimertinib and chemotherapy, osimertinib monotherapy as well compared to chemotherapy alone. So overall, the study met its primary endpoint, and I think it sheds light on how we manage our patients with early-stage lung cancer. I think osimertinib, we know that osimertinib is already FDA approved in the adjuvant space, but what we didn't really know is how was osimertinib going to work in the neoadjuvant space. And there are always situations, especially for stage III patients, where we are on the fence about, are these patients already close to being metastatic? They have, like, almost all these patients have micrometastatic disease, even if they have stage III. As we saw in the LAURA data, when you look at the control arm, it was like a very short PFS. Chemoradiation does nothing for those patients, and I think these patients have systemic mets, either gross or micrometastatic disease at onset. So, it's really important to incorporate osimertinib early in the treatment course. And I think, especially for the locally advanced patients, I think it's even more important to kind of incorporate osimertinib in the neoadjuvant space and get effective local control with surgery and treat them with adjuvant. I'm curious to hear your thoughts, Nate. Dr. Nate Pennell: I am a believer and have long been a believer in targeted adjuvant treatments, and, you know, it has always bothered me somewhat that we're using our far and away most effective systemic therapy; we wait until after they go through all their pre-op treatments, they go through surgery, then they go through chemotherapy, and then finally months later, they get their osimertinib, and it still clearly improves survival in the adjuvant setting. Why not just start the osimertinib as soon as you know that the patient has EGFR-mutant non-small cell lung cancer, and then you can move on to surgery and adjuvant treatment afterwards? And I think what was remarkable about this study is that all of these patients almost - 90% in each arm - went to surgery. So, you weren't harming them with the neoadjuvant treatment. And clearly better major pathologic response, nodal downstaging, event-free survival was better. But I don't know that this trial is ever going to show an overall survival difference between neoadjuvant versus just surgery and adjuvant treatment, given how effective the drug is in the adjuvant setting. Nonetheless, I think the data is compelling enough to consider this, certainly for our N2-positive, stage IIIA patients or a IIIB who might be otherwise surgical candidates. I think based on this, I would certainly consider that. Dr. Vamsi Velcheti: Yeah, and especially for EGFR, like even for stage IIIB patients, in the light of the LAURA study, those patients who do not do too well with chemoradiation. So you're kind of delaying effective systemic therapy, as you said, waiting for the chemoradiation to finish. So I think probably time to revisit how we kind of manage these locally advanced EGFR patients. Dr. Nate Pennell: Yep, I agree. Dr. Vamsi Velcheti: Nate, thank you so much for sharing your fantastic insights today on the ASCO Daily News Podcast. It's been an exciting ASCO again. You know, we've seen a lot of positive trials impacting our care of non-small cell lung cancer and small cell lung cancer patients. Dr. Nate Pennell: Thanks for inviting me, Vamsi. Always a pleasure to discuss these with you. Dr. Vamsi Velcheti: And thanks to our listeners for your time today. You will find links to all of the abstracts discussed today in the transcript of the episode. Finally, if you value the insights that you hear from the ASCO Daily News Podcast, please take a moment to rate, review, subscribe wherever you get your podcast. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. More on today's speakers:    Dr. Vamsi Velcheti   @VamsiVelcheti    Dr. Nathan Pennell   @n8pennell   Follow ASCO on social media:     @ASCO on Twitter     ASCO on Facebook     ASCO on LinkedIn   ASCO on BlueSky   Disclosures:   Dr. Vamsi Velcheti:   Honoraria: ITeos Therapeutics   Consulting or Advisory Role: Bristol-Myers Squibb, Merck, Foundation Medicine, AstraZeneca/MedImmune, Novartis, Lilly, EMD Serono, GSK, Amgen, Elevation Oncology, Taiho Oncology, Merus   Research Funding (Inst.): Genentech, Trovagene, Eisai, OncoPlex Diagnostics, Alkermes, NantOmics, Genoptix, Altor BioScience, Merck, Bristol-Myers Squibb, Atreca, Heat Biologics, Leap Therapeutics, RSIP Vision, GlaxoSmithKline   Dr. Nathan Pennell:     Consulting or Advisory Role: AstraZeneca, Lilly, Cota Healthcare, Merck, Bristol-Myers Squibb, Genentech, Amgen, G1 Therapeutics, Pfizer, Boehringer Ingelheim, Viosera, Xencor, Mirati Therapeutics, Janssen Oncology, Sanofi/Regeneron    Research Funding (Inst): Genentech, AstraZeneca, Merck, Loxo, Altor BioScience, Spectrum Pharmaceuticals, Bristol-Myers Squibb, Jounce Therapeutics, Mirati Therapeutics, Heat Biologics, WindMIL, Sanofi 

Audio, eng_t_norav_2025-06-25_lesson_zohar-la-am-vayetze-vehine-hashem-nitzav-alav_n4_p1. Lesson_part :: Daily_lesson 4 :: Lessons_series. Zohar for All

Video, eng_t_norav_2025-06-25_lesson_zohar-la-am-vayetze-vehine-hashem-nitzav-alav_n4_p1. Lesson_part :: Daily_lesson 4 :: Lessons_series. Zohar for All

Zohar for All. VaYetze. And Behold, the Lord Stood Above It

Audio, eng_t_norav_2025-06-25_lesson_zohar-la-am-vayetze-vehine-hashem-nitzav-alav_n4_p1. Lesson_part :: Daily_lesson 4 :: Lessons_series. Zohar for All

Video, eng_t_norav_2025-06-25_lesson_zohar-la-am-vayetze-vehine-hashem-nitzav-alav_n4_p1. Lesson_part :: Daily_lesson 4 :: Lessons_series. Zohar for All

Audio, spa_t_norav_2025-06-25_lesson_zohar-la-am-vayetze-vehine-hashem-nitzav-alav_n4_p1. Lesson_part :: Daily_lesson 4 :: Lessons_series. Zóhar para todos

Earthly heroes are those who stand tall in moments when others shrink back. They use their voice to speak truth, and their actions follow suit. In those moments of standing tall, they seem invincible.Pastor Chuck Swindoll presents Paul's final trial before Festus and King Agrippa in Acts 26. He stood tall by boldly proclaiming the truth of the gospel.Those who stand tall might not know the impact of their words or actions, but they do what is right regardless. They leave the results to God. How will you stand tall in response to this message? To support this ministry financially, visit: https://www.oneplace.com/donate/82/29

On this week's episode of WYHA, Anna is on maternity leave and we're back with another fun hotline! This episode - a listener's date stood her up for... a nap?! Does she give him another shot or is it a no-go? Tune in to hear our thoughts xSee omnystudio.com/listener for privacy information.

Listen in as editors discuss the big MRO news from this year's Paris Air Show, as well as what changed from the last time the industry convened in Le Bourget in 2023.

A listener writes “I was working as an HVAC Tech but was still learning the ropes and was being introduced into what being on call was like- long story short a coworker picked me up one night and we went up towards northern western Massachusetts for a no heat call. After spending some time in the basement with the hatchway doors open, my coworker went outside to use the bathroom and I followed him out to catch some fresh air and get something from the van. He goes out maybe 30/40 yards so the home owner doesn't see so he's pretty far from me. A few minutes pass by and as I'm sitting in the van (on my phone) I hear something walk up towards the van. After this thing had come up to the van with be sitting in it for over 10 minutes, there was a crack in the back door of the van so it wasn't open completely but you could see through about 3-4 inches. This thing made eye contact with me with 1 eye. Stood there for about 10-15 seconds and then blinked. After a few more seconds this thing took off incredibly fast after hearing some noise come from the open basement door.”

Yaqeen means belief, an unshaken trust, a light that holds steady even in the darkest hour. It is the quiet strength behind every decision, the invisible thread that pulls us forward when everything else falters. Yaqeen doesn't always roar; sometimes, it's a whisper that refuses to fade. In poetry, it becomes a force, of faith, of love, of conviction, that anchors the soul in a world of doubt. In this episode of Urdunama, we explore the depth of yaqeen through verses that speak of courage, clarity, and quiet confidence. Join us as we trace how poets have held on to belief, not as blind certainty, but as a powerful act of hope. Learn more about your ad choices. Visit megaphone.fm/adchoices

Mike Ferguson in the Morning-LA Dodgers claim they prevented ICE from operating at the stadium during a game. DHS says otherwise.-Col. William Dunn gives an update on what the next steps are regarding the U.S.'s involvement in Iran. -Mike Ferguson in the Morning Early Bird J. Monty joins in the fun!See omnystudio.com/listener for privacy information.

Verse by verse study through the book of Acts Chapter One and Verse Fifteen

In this sermon we look at how Paul handed the death threats being issued against him. How can believers today take courage in the face of adversity.

As Jesus stared down the barrel of a horrific death– drinking the cup of the wrath of God against all sin– He exhibited stunning courage. Even Judas and the soldiers were compelled to bow at the force of His proclamation, “I AM.” Their forced response to Jesus' courage should be our voluntary response: to fall down before Jesus in awe. Christ's courage at the end of His life compels the worship of all. “And being found in human form, he humbled himself by becoming obedient to the point of death, even death on a cross. Therefore God has highly exalted him and bestowed on him the name that is above every name, so that at the name of Jesus every knee should bow, in heaven and on earth and under the earth, and every tongue confess that Jesus Christ is Lord, to the glory of God the Father.” (Philippians 2:8-11) Take-Home Message: The courage of Christ compels me to worship. The Courageous Christ…  Stepped forward into darkness (1-4). Why did Judas betray Jesus? Wrong expectation Wrong treasure Wrong influence Stood up for the disciples (5-9). Submitted to His demise (10-12). Message: The Betrayal and Arrest of Jesus  Scripture: John 18:1-12 Simple. Authentic. Jesus. Prairiebible.org

6.13.25, Ben Standig from The Athletic joins Denton Day to update us on Commanders minicamp news and analyzes the NBA Finals series.

Dave and Brady Henderson break down what has stood out to them from Seahawks Training Camp, they lay out the expectations for the Seahawks defense in Mike Macdonald’s second season as head coach, they discuss some of the most notable minicamp holdouts around the NFL, and they look at what will happen with the members of the Seahawks 2022 draft class. 

On this episode of “Altitude Advantage,” team reporter Elisa Hernandez and lead writer Aric DiLalla discuss who stood out at Broncos mandatory minicamp, chat about the signing of running back J.K. Dobbins and recap the offseason. Who stood out at Broncos minicamp? (00:00-5:44) What the addition of J.K. Dobbins means for the Broncos (5:45-15:31) Final takeaways from the offseason, looking ahead to training camp (15:32-20:48) Want more of Altitude Advantage? Subscribe on Apple Podcasts, Spotify, TuneIn, Stitcher or wherever you get your podcasts.See omnystudio.com/listener for privacy information.

The post “Jesus came and stood among them and said, ‘Peace be with you.'” appeared first on Key Life.

"McElroy & Cubelic In The Morning" airs 7am-10am weekdays on WJOX-94.5!See omnystudio.com/listener for privacy information.

Alan Saunders and Zachary Smith discuss all things Pittsburgh Steelers. On today's episode, we go through each position group as we hit the reset button between minicamp and training camp. Who stood out? Who needs an impressive training camp to be on the right side of the roster bubble? Is Payton Wilson in for a larger role than we expected? What players should we be keeping an eye on at training camp for one reason or another? Let's go for another Steelers Afternoon Drive and discuss all this! Learn more about your ad choices. Visit megaphone.fm/adchoices

Tyrese Haliburton craves respect - but the people from whom he craves it are not worthy of worry! Colts minicamp wrapped today without incident, and the next time we see the Colts will be when training camp opens in six weeks. Myles Turner came in for the film session and then went home to rest up for tomorrow night's pivotal Game Four. Here is the link for the only autobiography ever published without praise for its author: https://www.amazon.com/Oops-Art-Learning-Mistakes-Adventures/dp/173420740X

Seth and Sean react to what Stefon Diggs said when finally repeatedly asked about the video with the pink bag, dive into rookie WR Jayden Higgins standing out at Texans minicamp, and react to something CJ Gardner-Johnson said that makes them sure he's adjusting to Houston well.

Alec Lewis, the Vikings beat writer at The Athletic, talks about what he saw Tuesday at Vikings mandatory minicamp. Lewis touches on J.J. McCarthy, Dallas Turner, and other players who stood out. He also gave his thoughts on Christian Darrisaw's return to the field and Josh Oliver's extension. This show is presented by First Resource Bank, which serves the needs of small businesses, entrepreneurs, and individuals in the Twin Cities and surrounding areas. For more information, here is their website: https://myfrbank.com/ And here is a link to all of their locations! https://myfrbank.com/locations-hours/

Meghan Ottolini and Justin Turpin break down the final day of Patriots minicamp live from Gillette Stadium, sharing key takeaways and analysis from the session. To learn more about listener data and our privacy practices visit: https://www.audacyinc.com/privacy-policy Learn more about your ad choices. Visit https://podcastchoices.com/adchoices

Alec Lewis, the Vikings beat writer at The Athletic, talks about what he saw Tuesday at Vikings mandatory minicamp. Lewis touches on J.J. McCarthy, Dallas Turner, and other players who stood out. He also gave his thoughts on Christian Darrisaw's return to the field and Josh Oliver's extension. This show is presented by First Resource Bank, which serves the needs of small businesses, entrepreneurs, and individuals in the Twin Cities and surrounding areas. For more information, here is their website: https://myfrbank.com/ And here is a link to all of their locations! https://myfrbank.com/locations-hours/

Brock and Salk share what jumped out to them in the Mariners loss to the Orioles yesterday, particularly on offense. Maura then shares her observations from everything she saw at Seahawks OTA's yesterday. In Blue 88, Brock dives in on Klint Kubiak's recent comments, a conversation he recently had with Chris Petersen and Sam Darnold building rapport with his wide receivers.

Brock and Salk share the QB that stood out at OTA's on Monday, and it may not be who you think. They then go through some of their OTA takeaways. In Blue 88, Brock dives in on Byron Murphy, Devon Witherspoon and one thing that shocked him from PFF's projected Seahawks starters in 2025.

Brock and Salk talk through what jumped out to them in the Mariners series win against the Twins. They also do a cheat check on all of Julio Rodriguez, Cal Raleigh and Jorge Polanco. In Blue 88, topics include Jarran Reed, Sam Darnold and what position group the Seahawks still could need to address.